Sg3 Management, LLC Altimmune, Inc. Call Options Transaction History

Sg3 Management, LLC

7 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q1 2023 May 15, 2023	SELL	$4.19 - $16.83 $97,627 - $392,138	-23,300 Closed	0 $0
Q4 2022 Feb 14, 2023	BUY	$8.74 - $16.45 $38,456 - $72,380	4,400 Added 18.88%	27,700 $455,000
Q3 2022 May 15, 2023	SELL	$10.67 - $22.41 $46,948 - $98,604	-4,400 Reduced 15.88%	23,300 $297,000
Q3 2022 Nov 14, 2022	BUY	$10.67 - $22.41 $248,611 - $522,153	23,300 New	23,300 $298,000
Q4 2021 Feb 15, 2022	SELL	$8.69 - $12.48 $681,296 - $978,432	-78,400 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$8.43 - $16.81 $575,769 - $1.15 Million	68,300 Added 676.24%	78,400 $887,000
Q1 2021 May 17, 2021	BUY	$12.71 - $24.31 $128,371 - $245,531	10,100 New	10,100 $143,000

204

39.7M

1.8M

1.04M

Ticker ALT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,025,300
Market Cap $312M
Description
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatit...

Get notified when there are updates to the investment portfolio of Sg3 Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Sg3 Management, LLC with notifications on news.